Summary of In a Major Shift, Cancer Drugs Go ‘Tissue-Agnostic’

Looking for the article?
We have the summary! Get the key insights in just 5 minutes.

In a Major Shift, Cancer Drugs Go ‘Tissue-Agnostic’ summary
Start getting smarter:
or see our plans

Rating

9

Qualities

  • Innovative
  • Scientific
  • Important

Recommendation

Ken Garber reports on a breakthrough in the treatment of cancer. He explains so-called “tissue-agnostic” drugs in thorough detail, proving his longstanding experience as a science writer. He uses complex medical terms to discuss biomedical mechanisms and drug development. However, he manages to break down the essential information for a general audience. getAbstract recommends this article to anyone interested in new developments in cancer treatment.

About the Author

Ken Garber is a science writer in Ann Arbor, Michigan with longstanding experience covering biology and medicine. He has written for Science, Nature, Nature Biotechnology and Nature Medicine. He is also a contributing correspondent for the Journal of the National Cancer Institute.

 

Summary

What are tissue-agnostic drugs?

Until recently, doctors treated cancerous tumors with a drug regimen that was dependent on the type of tissue the tumor originated from (e.g. breast, prostate, lung or skin). Novel, “tissue-agnostic” drugs act on tumors independent of their tissue of origin. They can attack any solid tumor presenting a specific genetic marker.

Which tissue-agnostic drugs are available or in development?

The US Food and Drug Administration (FDA) had approved Merck’s pembrolizumab (Keytruda) to exclusively treat...


More on this topic

Customers who read this summary also read

Technology Quarterly: Targeting Tumours
8
The Organoid Architect
9
Turning Piglets Into Personalized Avatars for Sick Kids
9
The Cancer Tree
8
The Greatest Hits of the Human Genome
8
Power Couple: Science and Technology
8

Related Channels

Comment on this summary